Morning Brief — Wednesday, July 29, 2026

Market Overview

The market is on edge as the Fed’s FOMC decision looms at 2 p.m. ET, with derivative markets pricing a jarring 36% probability of a surprise rate hike — an unusually high level of uncertainty for what’s typically a telegraphed event. Meanwhile, earnings season is delivering a bifurcated tape: AI-adjacent hardware (APH, RGEN) is ripping on beats and raised guidance, while fintech (SOFI) and aerospace (BA) are getting sold despite solid numbers. The Nasdaq has dropped five straight sessions on chipmaker pressure, but today’s catalyst calendar — Fed, Meta after close, and a slew of industrials — could reset the tone in either direction.

Claude’s Call

DOWN — The 36% probability of a surprise rate hike creates an asymmetric risk skew where even a hold decision could disappoint if Powell’s tone is hawkish; with the Nasdaq already in a five-day losing streak and chipmaker sentiment weak (NVDA bearish on WSB, MU under its 50-day SMA), the path of least resistance into the close is lower until the Fed resolves the uncertainty. Buy the dip after 2 p.m. if it’s a hold with dovish language — don’t front-run it.

Top Movers

CBZ (+16.68%) — $54.49 → $62.33 (+14.4% upside) Thesis: This is the real deal — Grant Thornton just announced a $5 billion cash acquisition of CBIZ, the largest professional services deal in 25+ years, making CBZ the fifth-largest provider in the U.S. overnight. Cash deals at this premium rarely fade; the stock is sitting at its 6-month high and the next technical target is the 1.272 fib extension at $62.33. The question is how much arb spread closes today. Levels: Exit at $62.33 (fib 1.272 extension — arb ceiling). Support at $47.48 (fib 23.6%), though you shouldn’t need it if the deal closes.

MANH (+14.96%) — $193.33 → $226.51 (+17.2% upside) Thesis: Manhattan Associates BEAT — revenue up $10.3M or ~3.6% above consensus, EPS beat by 6.1%, and three consecutive quarters of record bookings with 26% cloud revenue growth. The AI-driven supply chain software story is executing cleanly. Price broke above the 6-month high of $203.92 intraday, which is technically significant, but it’s already retesting that level — the real momentum play targets the 1.272 fib extension at $226.51. Levels: Exit at $226.51 (fib 1.272). Support at $184.32 (fib 23.6%) — that’s your stop zone if macro weighs on the name post-Fed.

APH (+9.51%) — $157.54 → $191.92 (+21.8% upside) Thesis: Amphenol absolutely crushed it — revenue beat by a wide margin at $8.76B (up 55% YoY), EPS beat by 13.2%, and Q3 guidance came in 7.1% above consensus. The AI datacom demand story is accelerating, not decelerating. Stock is trading below its 6-month high of $176.32 and has pulled back to the fib 61.8% support zone around $140-$154 before today’s rip — this is a breakout from compression, not a chase. Levels: Exit at $191.92 (fib 1.272 extension). Support at $154.41 (fib 38.2%) — lose that and the thesis is in trouble.

CLH (+8.39%) — $329.14 → $350.84 (+6.6% upside) Thesis: Clean Harbors BEAT — revenue up 11.9% YoY, GAAP EPS of $3.22 beat by 13.7%, and results topped expectations across the board in environmental/industrial services. The stock is at its 6-month high of $331.02 with RSI now at 74.6 — overbought territory — but the fundamental momentum here is genuine with a new board chair and clean execution. Small position, tight stop. Levels: Exit at $350.84 (fib 1.272 extension). Support at $313.83 (fib 23.6%) — RSI overbought means mean reversion risk is real today.

HURN (+12.77%) — $136.88 → $194.73 (+42.3% upside) Thesis: Huron Consulting delivered record Q2 RBR with 15.7% YoY growth, a 15.5% revenue beat, and — crucially — full-year guidance 2.4% above consensus with EPS 13.2% above estimates. The AI-driven digital services and managed healthcare demand is structurally sound. RSI at 73.9 signals near-term heat, but the stock is sitting at a 6-month high just breaching above the fib 38.2% resistance at $140.97 — not overextended yet with room to the 1.272 fib at $194.73. Levels: Exit at $194.73 (fib 1.272). Support at $121.56 (fib 61.8% — prior base) and $140.97 (recent resistance turned support).

KNSA (+25.03%) — $79.44 → $89.50 (+12.7% upside) Thesis: Kiniksa BEAT on revenue by 7.09% with ARCALYST Q2 sales of $243.6M (+55% YoY), raised full-year guidance to $980-$995M, and launched Phase 3 for KPL-387. This is a legitimate pharma re-rate on a drug that’s genuinely gaining market share in recurrent pericarditis. Price is at the 6-month high with no prior resistance overhead — the next target is the 1.272 fib extension at $89.50. Levels: Exit at $89.50 (fib 1.272), with potential extension to $102.30 on momentum. Support at $70.71 (fib 23.6%) — a big gap below current price, so position size accordingly.

NEO (+18.21%) — $15.84 → $17.89 (+12.9% upside) Thesis: NeoGenomics BEAT — revenue up 11.2% YoY to $201.7M, EPS $0.05 beat by $0.02, and full-year guidance raised to ~$804M. The cancer diagnostics NGS story is executing. Interestingly, RSI is only 24.74 — deeply oversold before this gap — meaning this move is a recovery from a washed-out base, not a blowoff top. Price broke above the fib 23.6% support at $13.62 and is now testing the 6-month high. Levels: Exit at $17.89 (fib 1.272 extension). Support at $13.62 (fib 23.6%) — a healthy amount of cushion below.

TEVA (+8.62%) — $34.40 → $38.51 (+11.9% upside) Thesis: Teva raised its full-year revenue guidance above expectations despite a mixed Q2 print — the market is rewarding forward visibility, not current results. RSI is neutral at 50 and price is approaching its 6-month high of $36.34. This is a generics/specialty pharma story with a low bar and a credible guide — not exciting, but technically constructive. Levels: Exit at $38.51 (fib 1.272 extension). Support at $33.27 (50-day SMA) — solid floor below.

RGEN (+10.9%) — $145.34 → $170.92 (+17.6% upside) Thesis: Repligen BEAT with Q2 revenue of $204M (+12% YoY, +13% organic), raised full-year guidance, and is actively pursuing the BioLife Solutions acquisition to expand in cell and gene therapy tools. The bioprocessing recovery story is gaining credibility. Price is testing resistance near its 20-day high of $148.55 — not overextended — with the 1.272 fib extension at $170.92 as the clean target. Levels: Exit at $170.92 (fib 1.272). Support at $132.31 (50-day SMA) and $135.93 (fib 38.2%).

Headlines to Watch

Grant Thornton acquires CBIZ in $5 billion cash deal — Largest professional services M&A in 25+ years; watch for arb spread compression in CBZ and sympathy moves in peer advisory/accounting names like FTI Consulting and Kforce.
JPMorgan maps Fed decision scenarios as Wall Street braces for surprise rate hike — A 36% probability priced into derivatives is unusually high; if the Fed holds and language is neutral, expect a sharp relief rally in rate-sensitive growth stocks — watch MANH, RGEN, GSHD.
Amphenol beats Q2 estimates, raises Q3 outlook on AI-driven demand — This is a tier-1 confirmation of AI infrastructure demand being real and durable; APH’s 55% revenue growth isn’t sympathy — it’s datacom hardware build-out at scale.
JetBlue reinstates 2026 outlook and sets 2028 EPS target of $1.00+ — The airline sector is getting a sympathy bid from JBLU’s forward guidance clarity, but the widening net loss to $247M (from $74M) means this is a story stock not a value play; delta, UAL, and WN may catch bids today.
Teva raises full-year revenue guidance — Generics/specialty pharma positive read-through; watch VTRS and other generic pharma names for sympathy rotation.
SOFI -9.65% despite earnings and guidance beat — Classic “sell the news” on a hyped fintech; CEO calling 2026 a “defining year” while the stock sells off 10% is a red flag — the market is skeptical of the growth premium. Hold off on the dip buy.
Nasdaq drops for 5th straight session; Fed decision at 2 p.m. — Don’t be a hero in front of the Fed today; the asymmetric risk is a surprise hike or hawkish hold that takes the Nasdaq down another leg. Cash is a position until 2:30 p.m.

Claude’s Top Picks

CBZ (+16.68% today, +35.08% week) — $54.49 → $62.33 (+14.4% upside) Valuation: No comps available, but this is a cash acquisition at a firm premium — the stock is trading below deal value, making valuation almost irrelevant here. Upside: Cash deal dynamics mean the arb spread should compress toward the acquisition price with limited downside unless the deal breaks (low probability given $5B committed by a major private firm). Risk: Deal falls through on regulatory grounds or antitrust review in the professional services space — though the DOJ track record on accounting firm mergers is permissive.

APH (+9.51% today, +0.02% week) — $157.54 → $191.92 (+21.8% upside) Valuation: No forward P/E comps provided, but 55% revenue growth with a 13.2% EPS beat and 7.1% guidance raise above consensus suggests the market hasn’t fully re-rated the AI infrastructure growth story into this stock. Upside: Q3 guidance at $9.35B midpoint is a step-function re-rate — the AI datacom cycle has legs through at least mid-2027, and APH has the connector/interconnect exposure to keep growing. Risk: Post-Fed rate spike compresses multiples on industrial tech names; stock is also retesting the SMA area after a pullback from $176 — needs to reclaim $162.79 (fib 23.6%) to confirm the breakout.

RGEN (+10.9% today, +6.1% week) — $145.34 → $170.92 (+17.6% upside) Valuation: No comps in data, but bioprocessing tools peers trade at 20-30x forward earnings on recovery cycles — RGEN’s 12% organic growth with raised guidance and active M&A (BioLife Solutions) puts it in the early innings of a recovery re-rate. Upside: The bioprocessing recovery is accelerating into H2 2026 with consumable demand and the pending BioLife acquisition adding ~$100M in revenue scale; RSI at 50 means no overbought risk yet. Risk: BioLife acquisition falls through or integration costs disappoint in Q3; the stock is also still 7% below its 6-month high of $156.37 — needs to clear that to confirm trend reversal.

MANH (+14.96% today, +29.66% week) — $193.33 → $226.51 (+17.2% upside) Valuation: EXPENSIVE — forward P/E of 34.7x vs. peer median of 12.3x, EV/EBITDA 33.9x vs. 13.6x peer median. However, this premium is being paid for record bookings and 26% cloud growth — the question is whether execution justifies it. Upside: Three consecutive quarters of record bookings, RPO expansion, and 26% cloud revenue growth mean the backlog supports forward estimates well. When SaaS supply chain names re-rate, they move fast and far — the 1.272 fib at $226.51 is achievable in 2-3 weeks. Risk: The valuation premium is extreme (nearly 3x peer median P/E) — any macro deterioration or Fed surprise today could compress multiples sharply on a 35x forward name; the stock is already 15% above the SMA-50 at $148.

HURN (+12.77% today, +22.71% week) — $136.88 → $194.73 (+42.3% upside) Valuation: No forward comps in data, but professional services firms with 15%+ organic revenue growth and 15% EPS beats at this market cap are historically cheap — consulting peers like HCI and Kforce trade at 12-18x forward earnings. Upside: Record Q2 RBR, guidance 2.4% above consensus, and the AI-driven healthcare digital services vertical is a genuine structural driver — not cyclical consulting hours but recurring software-adjacent work. Risk: RSI at 73.9 is overbought on a near-term basis — a Fed surprise could trigger a sharp giveback; stop at $121.56 (fib 61.8%) represents a significant drawdown if macro deteriorates.

Avoid

BRAI (+26.74%) — Trading at its 20-day high of $7.21 with volume ratio at only 0.58x average — this is a micro-cap AI narrative stock ($7 price, no SMA-200 available) with the catalyst being a product launch (ARIA for real estate) from two weeks ago. The 26% move on below-average volume with a 50.0 momentum score and RSI of 58.6 screams low-conviction pump. The 6-month high is $14.84, meaning there’s no nearby resistance ceiling, which sounds good until you realize there’s also no institutional floor. Avoid.

KNSA (+25.03%) — The earnings beat and guidance raise are real, but a 25% single-day move to a new 6-month high on volume ratio of only 0.12x average is deeply suspicious. This is a thinly-traded pharma name and the low volume on a massive move suggests a thin order book, not institutional accumulation. The fib 23.6% support at $70.71 is $9 below current price — chasing here with no vol confirmation is dangerous.

JBLU (+10.5%) — Net loss WIDENED to $247M from $74M a year ago, and the 10.5% rally is entirely predicated on the company reinstating guidance it previously pulled and setting a 2028 EPS target of $1.00+. That’s a two-year promise from a carrier with a $6 stock and a deteriorating balance sheet. The fib 1.272 extension is only at $7.12, and the 6-month high is $6.46 — limited upside and the fundamental story is airlines burning cash while fuel costs remain volatile. Sector sympathy trades in airlines historically fade within 48-72 hours.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish, 743 mentions, 3,782 upvotes) Claude says: DISAGREE — The chart is broken. MU is at $832, down 31% from its 6-month high of $1,213, sitting below both the 50-day SMA ($960) and the fib 50% support at $767 acting as a floor. SNDK’s mixed earnings and the broader chipmaker rout driving the Nasdaq’s 5-session losing streak are direct read-throughs. 80% bullish sentiment when the chart is in a confirmed downtrend is WSB trying to catch a falling knife — wait for a reclaim of the $872 fib 38.2% level before considering a position.

SNDK — WSB says: MIXED (55% bullish, 483 mentions, 5,285 upvotes) Claude says: AGREE (partially) — The 5,285 upvotes on mixed sentiment reflects genuine uncertainty, which is the honest read. SNDK is down 53% from its 6-month high of $2,335, sitting at $1,088 which is the 20-day low — technically it’s at a potential base but the fib 61.8% support is still at $1,218. This is a capitulation zone, not a clear buy signal. High-risk spec trade only, not a conviction buy.

MSFT — WSB says: MIXED (55% bullish, 228 mentions, 823 upvotes) Claude says: DISAGREE (on the bullish lean) — MSFT reported $16.80 EPS and barely moved (-0.43%), which is a classic “priced for perfection” reaction. The stock sits at $391.50, below its 50-day SMA of $397.87 and well below its 6-month high of $460.52. The fib 61.8% support at $393.97 is the near-term battleground — with the Fed decision today and MSFT already struggling to hold its SMA, the risk-reward doesn’t favor chasing. Low-volume (0.06x) confirms no institutional urgency.

SPCX — WSB says: MIXED (55% bullish, 166 mentions, 498 upvotes) Claude says: DISAGREE — SPCX is down 45% from its 6-month high of $211.39 and is sitting at $115.38, barely above its 6-month low of $113.50 with no 50-day or 200-day SMA available (new or thinly-traded instrument). Volume ratio is 0.05x — essentially illiquid. WSB attention on a thinly-traded, illiquid vehicle down 45% from highs screams bottom-fishing in something with no institutional support. Stay away.

NVDA — WSB says: BEARISH (30% bullish, 150 mentions, 370 upvotes) Claude says: AGREE — Rare case where WSB’s bearish lean matches the chart. NVDA at $196.66 is below its 50-day SMA ($207.19) and trading near the 61.8% fib support at $191.90 which is now being tested. The 6-month high was $235.47 — the stock has retraced 17% and the Nasdaq’s 5-session losing streak with chipmaker-specific pressure makes this a wait-for-confirmation situation. The $200.22 fib 50% level is the first resistance to reclaim. Bears have the momentum right now.

Earnings Scorecard

BE (Bloom Energy) — REPORTED | Stock: +10.3% First $1 billion revenue quarter with a stronger 2026 profit outlook — the market reaction is justified. Bloom crossed a key psychological revenue milestone and raised earnings guidance, which is exactly the combination that attracts new institutional buyers. Not a chase here — stock needs to digest the move, but dip-buyers should watch for confirmation.

SOFI (SoFi Technologies) — BEAT | Stock: -9.65% Beat on both revenue and EPS, CEO calling it a “defining year,” yet down nearly 10% — this is the classic “sell the news” on a premium-valued fintech. The market is telling you the beat was expected and the stock was priced for it. Hold off on buying the dip — when a beat produces a 10% selloff, the market is re-rating the growth premium lower, not creating a bargain.

CAR (Avis Budget) — MISS | Stock: -6.81% EPS of -$18.91 with headlines citing a “massive earnings miss” driven by a shift in rental trends — the reaction is justified and arguably insufficient. Rental car pricing normalization is a structural headwind, not a one-quarter blip. Sell-the-rip — any bounce is likely short-lived until the business model reset is complete.

STX (Seagate Technology) — BEAT | Stock: +5.65% Beat with $10.54 EPS and Morningstar noting a “new pricing regime” — the AI storage cycle is real and Seagate is one of the direct beneficiaries. The +5.65% reaction feels underdone given the multi-year growth runway commentary. Buy-the-dip on any pullback — hard disk drive demand from AI data centers is a genuine secular driver.

BSX (Boston Scientific) — BEAT | Stock: -5.48% Beat estimates but profit forecast cut due to a Watchman slowdown — the -5.5% reaction is justified given forward guidance compression. When a medical device company cuts its earnings outlook even on a revenue beat, the market correctly re-rates it lower. Wait for the new floor before considering an entry — Watchman deceleration needs to be quantified.

F (Ford Motor) — BEAT | Stock: +4.08% Beat and raised 2026 guidance with a Citi upgrade — the +4% reaction is a fair read for an auto OEM in a mixed macro environment. Ford’s EV/legacy balance and tariff exposure remain overhangs. Neutral — the beat is real but the 15-20% upside to analyst targets ($15.20) is capped by structural headwinds.

XOM (ExxonMobil) — REPORTED | Stock: +3.49% $5.88 EPS with upbeat commentary on July 31 full earnings — the +3.5% move makes sense as a pre-print warmup. Oil spiked on Iran news, adding a tactical tailwind. Hold — the real catalyst is the July 31 full report; today’s move is anticipatory positioning.

BA (Boeing) — REPORTED | Stock: -2.58% Record airplane deliveries and revenue growth, yet -2.58% — the market is clearly skeptical of Boeing’s earnings quality given the new Air Force One charge and years of execution risk. The reaction feels slightly overdone on a day with good delivery numbers, but trust in Boeing’s management takes years to rebuild. Neutral — not a buy until guidance is consistently reliable.

HUM (Humana) — BEAT | Stock: -1.28% Beat estimates and reaffirmed outlook, yet -1.3% — managed care is under persistent margin pressure from Medicare Advantage rate cuts and elevated medical cost ratios. The mild negative reaction despite a beat tells you the market doesn’t trust the reaffirmed guidance. Hold — not a buy until medical loss ratio trajectory improves.

PYPL (PayPal) — BEAT | Stock: +1.01% EPS of $5.33 with the CEO keeping “door open on potential deals” — a modest +1% reaction to a beat signals the market is waiting for M&A clarity before re-rating the stock. The takeover buzz is keeping a floor under it. Neutral — optionality is interesting but not actionable until a deal is named.

KO (Coca-Cola) — BEAT | Stock: +0.71% Best earnings day since 2009 per headlines, driven by World Cup tailwinds and upbeat guidance — yet +0.71% is muted. Analysts flagging limited upside and suggesting PepsiCo offers better value is the right read. Hold — it’s a quality defensive name but not a swing trade catalyst.

MSFT (Microsoft) — REPORTED | Stock: -0.43% $16.80 EPS, essentially flat reaction — when the world’s largest software company beats estimates and moves less than half a percent, it tells you the bar was already priced in. Not a buy here — needs to reclaim the $397.87 SMA before it’s technically investable on the long side.

ORLY (O’Reilly Automotive) — REPORTED | Stock: -1.82% -1.82% on earnings — auto parts retail is facing lapping tough comps and consumer softness in discretionary spending. Neutral — wait for more clarity on the consumer spending backdrop before re-engaging.

ARM (Arm Holdings) — REPORTED | Stock: -1.68% $0.86 EPS and a mild -1.68% reaction in a weak chip tape — the stock is holding up relatively well given the sector headwinds. Neutral — needs broader chip sentiment to stabilize before ARM can make a real move.

This brief is for informational purposes only and does not constitute investment advice. All levels and targets are based on technical analysis and are probabilistic, not guaranteed.